Grifols, S.A. (GIKLY)
USD 5.13
(0.0%)
USD 5.13
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 10.11 Billion EUR | 3.77% |
| 2022 | 9.75 Billion EUR | 4.57% |
| 2021 | 9.32 Billion EUR | 34.91% |
| 2020 | 6.91 Billion EUR | -2.75% |
| 2019 | 7.1 Billion EUR | 13.01% |
| 2018 | 6.28 Billion EUR | 4.62% |
| 2017 | 6.01 Billion EUR | 23.05% |
| 2016 | 4.88 Billion EUR | 2.66% |
| 2015 | 4.75 Billion EUR | 12.3% |
| 2014 | 4.23 Billion EUR | 57.56% |
| 2013 | 2.68 Billion EUR | -3.19% |
| 2012 | 2.77 Billion EUR | -6.05% |
| 2011 | 2.95 Billion EUR | 245.03% |
| 2010 | 857.02 Million EUR | 4.88% |
| 2009 | 817.17 Million EUR | 71.76% |
| 2008 | 475.76 Million EUR | 27.39% |
| 2007 | 373.48 Million EUR | 10.76% |
| 2006 | 337.21 Million EUR | 14.84% |
| 2005 | 293.62 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 11.39 Billion EUR | 12.63% |
| 2024 Q2 | 10.63 Billion EUR | -6.62% |
| 2023 Q4 | 10.11 Billion EUR | -8.49% |
| 2023 Q3 | 11.05 Billion EUR | 1.1% |
| 2023 Q1 | 10.75 Billion USD | 10.36% |
| 2023 Q2 | 10.93 Billion EUR | 1.64% |
| 2023 FY | 10.11 Billion EUR | 3.77% |
| 2022 Q4 | 9.75 Billion USD | 0.0% |
| 2022 FY | 9.75 Billion EUR | 4.57% |
| 2022 Q2 | 9.55 Billion EUR | 0.0% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2021 Q1 | 7.36 Billion EUR | 6.61% |
| 2021 Q2 | 7.6 Billion EUR | 3.22% |
| 2021 Q3 | 10.11 Billion EUR | 33.02% |
| 2021 FY | 9.32 Billion EUR | 34.91% |
| 2021 Q4 | 10.11 Billion USD | 0.0% |
| 2020 FY | 6.91 Billion EUR | -2.75% |
| 2020 Q4 | 6.91 Billion EUR | -1.94% |
| 2020 Q3 | 7.04 Billion EUR | 0.07% |
| 2020 Q2 | 7.04 Billion EUR | -2.11% |
| 2020 Q1 | 7.19 Billion EUR | 1.24% |
| 2019 Q4 | 7.1 Billion EUR | -2.9% |
| 2019 FY | 7.1 Billion EUR | 13.01% |
| 2019 Q1 | 329.96 Million EUR | -94.75% |
| 2019 Q2 | 6.99 Billion EUR | 2018.57% |
| 2019 Q3 | 7.31 Billion EUR | 4.7% |
| 2018 Q1 | 174.4 Million EUR | -97.1% |
| 2018 FY | 6.28 Billion EUR | 4.62% |
| 2018 Q4 | 6.28 Billion EUR | -1.17% |
| 2018 Q3 | 6.36 Billion EUR | 3.5% |
| 2018 Q2 | 6.14 Billion EUR | 3425.43% |
| 2017 Q4 | 6.01 Billion EUR | 3424.48% |
| 2017 Q2 | 6.14 Billion EUR | 3771.84% |
| 2017 FY | 6.01 Billion EUR | 23.05% |
| 2017 Q1 | 158.81 Million EUR | -96.75% |
| 2017 Q3 | 170.55 Million EUR | -97.23% |
| 2016 Q4 | 4.88 Billion EUR | 4.86% |
| 2016 Q2 | 4.67 Billion EUR | 1.97% |
| 2016 FY | 4.88 Billion EUR | 2.66% |
| 2016 Q1 | 4.58 Billion EUR | -3.69% |
| 2016 Q3 | 4.65 Billion EUR | -0.32% |
| 2015 FY | 4.75 Billion EUR | 12.3% |
| 2015 Q4 | 4.75 Billion EUR | 4.26% |
| 2015 Q3 | 4.56 Billion EUR | 0.44% |
| 2015 Q2 | 4.54 Billion EUR | -3.67% |
| 2015 Q1 | 4.71 Billion EUR | 11.33% |
| 2014 Q3 | 4.12 Billion EUR | 7.15% |
| 2014 Q2 | 3.84 Billion EUR | 0.96% |
| 2014 FY | 4.23 Billion EUR | 57.56% |
| 2014 Q1 | 3.8 Billion EUR | 41.65% |
| 2014 Q4 | 4.23 Billion EUR | 2.83% |
| 2013 Q1 | 2.82 Billion EUR | 1.72% |
| 2013 Q2 | 2.81 Billion EUR | -0.54% |
| 2013 FY | 2.68 Billion EUR | -3.19% |
| 2013 Q3 | 2.72 Billion EUR | -2.98% |
| 2013 Q4 | 2.68 Billion EUR | -1.37% |
| 2012 Q1 | 2.74 Billion EUR | -7.06% |
| 2012 Q4 | 2.77 Billion EUR | -1.54% |
| 2012 Q3 | 2.82 Billion EUR | -3.06% |
| 2012 FY | 2.77 Billion EUR | -6.05% |
| 2012 Q2 | 2.91 Billion EUR | 5.9% |
| 2011 Q4 | 2.95 Billion EUR | -0.1% |
| 2011 Q2 | 3.15 Billion EUR | 0.0% |
| 2011 FY | 2.95 Billion EUR | 245.03% |
| 2011 Q3 | 2.95 Billion EUR | -6.11% |
| 2010 Q4 | 857.02 Million EUR | 0.0% |
| 2010 FY | 857.02 Million EUR | 4.88% |
| 2009 FY | 817.17 Million EUR | 71.76% |
| 2008 FY | 475.76 Million EUR | 27.39% |
| 2007 FY | 373.48 Million EUR | 10.76% |
| 2006 FY | 337.21 Million EUR | 14.84% |
| 2005 FY | 293.62 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | 64.602% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 75.599% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -10053.385% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -23835.837% |
| Novartis AG | 26.34 Billion USD | 61.601% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -24939.593% |